All treatments
Treatment
Bavencio 20 mg/mL concentrate for solution for infusion clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A–BRAVE-Trial. ADJUVANT TREATMENT FOR HIGH-RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS WITH THE ANTI-PD-L1 ANTIBODY AVELUMAB: A PHASE III RANDOMIZED TRIAL
This study is looking at a new treatment called Bavencio for a specific type of breast cancer (triple negative). It's a large study to see if adding Bavencio after initial treatment can help people live longer without their cancer coming back.
For: Breast CancerItaly - AuthorisedPhase III and phase IV (Integrated)
Avelumab Short Maintenance Trial
This study looks at a medicine called Bavencio for bladder cancer (urothelial cancer). It aims to see if patients live longer (18 months or more) when receiving this medicine after initial treatment. It is a late-stage trial to understand more about its effects.
For: urothelial cancer, Bladder cancer, muscle invasive bladder cancerNetherlands